BackBrooklyn ImmunoTherapeutics Overview

Brooklyn ImmunoTherapeutics EBIT

EBIT (Earnings Before Interest and Taxes) analysis for BTX.

Quarterly EBIT

-$2.26M
↑ 58.96% YoY

As of Sep 30, 2024

Annual EBIT (TTM)

-$18.74M
↑ 3.83% YoY

Trailing 12 months ending Sep 30, 2024

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin